BACKGROUND: Growth-differentiation factor-15 (GDF-15) is emerging as a prognostic marker in patients with cardiovascular disease (CVD), but its prognostic value in community-dwelling adults has not been reported. We hypothesized that GDF-15 would add incremental power for prediction of mortality in a population of community-dwelling older adults without known heart disease. METHODS AND RESULTS: We measured plasma GDF-15, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and C-reactive protein levels in 1391 Rancho Bernardo Study participants, mean age 70 years, with no history of CVD and followed them for a mean of 11 years. In models adjusted for traditional CVD risk factors, GDF-15 was a robust predictor of all-cause, cardiovascular, and noncardiovascular mortality. GDF-15 was a stronger predictor of all-cause mortality than either NT-proBNP or C-reactive protein (hazard ratio [95% confidence interval] per SD log(10) units 1.5 [1.3 to 1.8], P<0.0001 for GDF-15 versus 1.3 [1.2 to 1.5], P<0.0001 for NT-proBNP; C-reactive protein was not a significant predictor). Among biomarkers considered, only GDF-15 predicted noncardiovascular death (hazard ratio 1.6 [1.4 to 2.0], P<0.0001). Growth differentiation factor-15 improved discrimination and modestly but significantly improved reclassification for all-cause and noncardiovascular mortality with borderline improvement for cardiovascular mortality; NT-proBNP significantly improved reclassification for all-cause and for cardiovascular mortality; C-reactive protein did not improve reclassification for any end point tested. Participants in the highest quartile of both GDF-15 and NT-proBNP had an increased risk of death compared with participants with only NT-proBNP elevated (hazard ratio 1.5 [1.1 to 2.0], P=0.01). CONCLUSIONS: Growth differentiation factor-15 is a strong predictor of all-cause, cardiovascular, and noncardiovascular mortality in community-dwelling older individuals, adding incremental value to traditional risk factors and to NT-proBNP and C-reactive protein levels.
BACKGROUND:Growth-differentiation factor-15 (GDF-15) is emerging as a prognostic marker in patients with cardiovascular disease (CVD), but its prognostic value in community-dwelling adults has not been reported. We hypothesized that GDF-15 would add incremental power for prediction of mortality in a population of community-dwelling older adults without known heart disease. METHODS AND RESULTS: We measured plasma GDF-15, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and C-reactive protein levels in 1391 Rancho Bernardo Study participants, mean age 70 years, with no history of CVD and followed them for a mean of 11 years. In models adjusted for traditional CVD risk factors, GDF-15 was a robust predictor of all-cause, cardiovascular, and noncardiovascular mortality. GDF-15 was a stronger predictor of all-cause mortality than either NT-proBNP or C-reactive protein (hazard ratio [95% confidence interval] per SD log(10) units 1.5 [1.3 to 1.8], P<0.0001 for GDF-15 versus 1.3 [1.2 to 1.5], P<0.0001 for NT-proBNP; C-reactive protein was not a significant predictor). Among biomarkers considered, only GDF-15 predicted noncardiovascular death (hazard ratio 1.6 [1.4 to 2.0], P<0.0001). Growth differentiation factor-15 improved discrimination and modestly but significantly improved reclassification for all-cause and noncardiovascular mortality with borderline improvement for cardiovascular mortality; NT-proBNP significantly improved reclassification for all-cause and for cardiovascular mortality; C-reactive protein did not improve reclassification for any end point tested. Participants in the highest quartile of both GDF-15 and NT-proBNP had an increased risk of death compared with participants with only NT-proBNP elevated (hazard ratio 1.5 [1.1 to 2.0], P=0.01). CONCLUSIONS:Growth differentiation factor-15 is a strong predictor of all-cause, cardiovascular, and noncardiovascular mortality in community-dwelling older individuals, adding incremental value to traditional risk factors and to NT-proBNP and C-reactive protein levels.
Authors: Tibor Kempf; Stephan von Haehling; Timo Peter; Tim Allhoff; Mariantonietta Cicoira; Wolfram Doehner; Piotr Ponikowski; Gerasimos S Filippatos; Piotr Rozentryt; Helmut Drexler; Stefan D Anker; Kai C Wollert Journal: J Am Coll Cardiol Date: 2007-08-24 Impact factor: 24.094
Authors: David A Brown; Robyn L Ward; Philip Buckhaults; Tao Liu; Katharine E Romans; Nicholas J Hawkins; Asne R Bauskin; Kenneth W Kinzler; Bert Vogelstein; Samuel N Breit Journal: Clin Cancer Res Date: 2003-07 Impact factor: 12.531
Authors: David A Brown; Samuel N Breit; Julie Buring; W Douglas Fairlie; Asne R Bauskin; Tao Liu; Paul M Ridker Journal: Lancet Date: 2002-06-22 Impact factor: 79.321
Authors: Sophie Shnaper; Isabelle Desbaillets; David A Brown; Anastasia Murat; Eugenia Migliavacca; Myriam Schluep; Sandrine Ostermann; Marie-France Hamou; Roger Stupp; Samuel N Breit; Nicolas de Tribolet; Monika E Hegi Journal: Int J Cancer Date: 2009-12-01 Impact factor: 7.396
Authors: Dong Hoon Lee; Young Yang; Soon Jung Lee; Kun-Yong Kim; Tae Hyeon Koo; Sun Mi Shin; Kyu Sang Song; Young Ho Lee; Yung-Jin Kim; Jung Joon Lee; Inpyo Choi; Jeong-Hyung Lee Journal: Cancer Res Date: 2003-08-01 Impact factor: 12.701
Authors: Anand Rohatgi; Parag Patel; Sandeep R Das; Colby R Ayers; Amit Khera; Abelardo Martinez-Rumayor; Jarett D Berry; Darren K McGuire; James A de Lemos Journal: Clin Chem Date: 2011-11-07 Impact factor: 8.327
Authors: Viji Nair; Cassianne Robinson-Cohen; Michelle R Smith; Keith A Bellovich; Zeenat Yousuf Bhat; Maria Bobadilla; Frank Brosius; Ian H de Boer; Laurent Essioux; Ivan Formentini; Crystal A Gadegbeku; Debbie Gipson; Jennifer Hawkins; Jonathan Himmelfarb; Bryan Kestenbaum; Matthias Kretzler; Maria Chiara Magnone; Kalyani Perumal; Susan Steigerwalt; Wenjun Ju; Nisha Bansal Journal: J Am Soc Nephrol Date: 2017-02-03 Impact factor: 10.121
Authors: Abhinav Sharma; Susanna R Stevens; Joseph Lucas; Mona Fiuzat; Kirkwood F Adams; David J Whellan; Mark P Donahue; Dalane W Kitzman; Ileana L Piña; Faiez Zannad; William E Kraus; Christopher M O'Connor; G Michael Felker Journal: JACC Heart Fail Date: 2017-10 Impact factor: 12.035
Authors: Ifigeneia V Mavragani; Danae A Laskaratou; Benjamin Frey; Serge M Candéias; Udo S Gaipl; Katalin Lumniczky; Alexandros G Georgakilas Journal: Toxicol Res (Camb) Date: 2015-08-11 Impact factor: 3.524
Authors: Vivek Narayan; Elizabeth W Thompson; Biniyam Demissei; Jennifer E Ho; James L Januzzi; Bonnie Ky Journal: J Am Coll Cardiol Date: 2020-06-02 Impact factor: 24.094
Authors: Thomas J Wang; Kai C Wollert; Martin G Larson; Erin Coglianese; Elizabeth L McCabe; Susan Cheng; Jennifer E Ho; Michael G Fradley; Anahita Ghorbani; Vanessa Xanthakis; Tibor Kempf; Emelia J Benjamin; Daniel Levy; Ramachandran S Vasan; James L Januzzi Journal: Circulation Date: 2012-08-20 Impact factor: 29.690